Liposomal dexamethasone(Liposomal dexamethasone) - 在研适应症：转移性去势抵抗性前列腺癌_专利_临床

概要

基本信息

药物类型

小分子化药

别名-

靶点-

作用机制-

治疗领域

肿瘤泌尿生殖系统疾病

在研适应症

转移性去势抵抗性前列腺癌

非在研适应症-

原研机构

Centre for Human Drug Research

在研机构

Centre for Human Drug Research

非在研机构-

最高研发阶段临床1期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

100 项与 Liposomal dexamethasone 相关的临床结果

登录后查看更多信息

100 项与 Liposomal dexamethasone 相关的转化医学

登录后查看更多信息

100 项与 Liposomal dexamethasone 相关的专利（医药）

登录后查看更多信息

1

项与 Liposomal dexamethasone 相关的文献（医药）

2024-10-22·ACS Nano

Neutrophil Hitchhiking Enhances Liposomal Dexamethasone Therapy of Sepsis

Article

作者: Martin, Lukas ; Metselaar, Josbert Maarten ; Lammers, Twan ; Schürholz, Tobias ; Bartneck, Matthias ; Mathur, Ritvik ; Storm, Gert ; Sofias, Alexandros Marios ; Press, Adrian T. ; Koczera, Patrick ; Kiessling, Fabian ; Marx, Gernot ; Brück, Julian ; Elsafy, Sara ; Hornef, Mathias

Sepsis is characterized by a dysregulated immune response and is very difficult to treat. In the cecal ligation and puncture (CLP) mouse model, we show that nanomedicines can effectively alleviate systemic and local septic events by targeting neutrophils. Specifically, by decorating the surface of clinical-stage dexamethasone liposomes with cyclic arginine-glycine-aspartic acid (cRGD) peptides, we promote their engagement with neutrophils in the systemic circulation, leading to their prominent accumulation at primary and secondary sepsis sites. cRGD-targeted dexamethasone liposomes potently reduce immature circulating neutrophils and neutrophil extracellular traps in intestinal sepsis induction sites and the liver. Additionally, they mitigate inflammatory cytokines systemically and locally while preserving systemic IL-10 levels, contributing to lower IFN-γ/IL-10 ratios as compared to control liposomes and free dexamethasone. Our strategy addresses sepsis at the cellular level, illustrating the use of neutrophils both as a therapeutic target and as a chariot for drug delivery.

100 项与 Liposomal dexamethasone 相关的药物交易

登录后查看更多信息